The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.EBI
Guangdong Pharmaceutical University
Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.EBI
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists.EBI
Guangdong Pharmaceutical University
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.EBI
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.EBI
Guangdong Pharmaceutical University
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.EBI
Guangdong Pharmaceutical University
Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.EBI
Guangdong Pharmaceutical University
Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.EBI
Guangdong Pharmaceutical University
Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.EBI
Guangdong Pharmaceutical University
Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.EBI
Guangdong Pharmaceutical University
Design, synthesis and biological activity of deuterium-based FFA1 agonists with improved pharmacokinetic profiles.EBI
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.EBI
Guangdong Pharmaceutical University
Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents.EBI
Guangdong Pharmaceutical University
Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.EBI
Guangdong Pharmaceutical University
Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.EBI
Guangdong Pharmaceutical University
Improving metabolic stability with deuterium: The discovery of GPU-028, a potent free fatty acid receptor 4 agonists.EBI
Guangdong Pharmaceutical University